Fibrobiologics Inc
FBLG0.609USD
-0.040-6.18%
Handelsschluss 08/04, 16:00（ET）Kurse um 15 Minuten verzögert
24.86MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Fibrobiologics Inc Unternehmen
FibroBiologics, Inc. is a cell therapy regenerative medicine company. The Company is focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with unmet medical needs, including degenerative disc disease, multiple sclerosis, wound healing, and certain cancers, and potential extension of life applications including thymic and splenic involution reversal. Its product candidates include CybroCell, CYMS101 and CYWC628. CybroCell is an allogeneic fibroblast cell-based therapy for degenerative disc disease. This technology is being designed as an alternative method for repairing the cartilage of the intervertebral disc (or any other articular cartilage). The Company is developing CYMS101 as an allogeneic fibroblast cell-based therapy to treat Multiple sclerosis (MS) and has completed the Phase I study. The Company is developing CYWC628 as an allogeneic fibroblast cell-based therapy for wound healing.
Unternehmensinformationen
BörsenkürzelFBLG
Name des UnternehmensFibrobiologics Inc
IPO-datumJan 31, 2024
CEOMr. Pete O'Heeron
Anzahl der mitarbeiter13
WertpapierartOrdinary Share
GeschäftsjahresendeJan 31
Addresse455 E. Medical Center Blvd
StadtHOUSTON
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl77598
Telefon12816715150
Websitehttps://fibrobiologics.com/
BörsenkürzelFBLG
IPO-datumJan 31, 2024
CEOMr. Pete O'Heeron
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Hamid Khoja, Ph.D.
Dr. Hamid Khoja, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
31.25K
+177.78%
Dr. Victoria Niklas, M.D.
Dr. Victoria Niklas, M.D.
Independent Director
Independent Director
7.50K
--
Mr. Robert E. Hoffman, CPA
Mr. Robert E. Hoffman, CPA
Director
Director
7.50K
--
Mr. Nic Johnson
Mr. Nic Johnson
IR Contact Officer
IR Contact Officer
--
--
Mr. Ruben Garcia
Mr. Ruben Garcia
General Counsel
General Counsel
--
--
Mr. Pete O'Heeron
Mr. Pete O'Heeron
Chairman of the Board, Chief Executive Officer, Founder
Chairman of the Board, Chief Executive Officer, Founder
--
--
Mr. Richard Cilento, Jr.
Mr. Richard Cilento, Jr.
Independent Director
Independent Director
--
--
Ms. Stacy Coen
Ms. Stacy Coen
Independent Director
Independent Director
--
--
Mr. Matthew Link
Mr. Matthew Link
Independent Director
Independent Director
--
--
Mr. Jason D. Davis
Mr. Jason D. Davis
Chief Financial Officer
Chief Financial Officer
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Hamid Khoja, Ph.D.
Dr. Hamid Khoja, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
31.25K
+177.78%
Dr. Victoria Niklas, M.D.
Dr. Victoria Niklas, M.D.
Independent Director
Independent Director
7.50K
--
Mr. Robert E. Hoffman, CPA
Mr. Robert E. Hoffman, CPA
Director
Director
7.50K
--
Mr. Nic Johnson
Mr. Nic Johnson
IR Contact Officer
IR Contact Officer
--
--
Mr. Ruben Garcia
Mr. Ruben Garcia
General Counsel
General Counsel
--
--
Mr. Pete O'Heeron
Mr. Pete O'Heeron
Chairman of the Board, Chief Executive Officer, Founder
Chairman of the Board, Chief Executive Officer, Founder
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Mon, Jul 28
Aktualisiert: Mon, Jul 28
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
O'Heeron (Peter)
14.10%
Golden Knight Inc LP
5.10%
BlackRock Institutional Trust Company, N.A.
3.90%
The Vanguard Group, Inc.
3.39%
Geode Capital Management, L.L.C.
1.47%
Other
72.05%
Aktionäre
Aktionäre
Anteil
O'Heeron (Peter)
14.10%
Golden Knight Inc LP
5.10%
BlackRock Institutional Trust Company, N.A.
3.90%
The Vanguard Group, Inc.
3.39%
Geode Capital Management, L.L.C.
1.47%
Other
72.05%
Aktionärstypen
Aktionäre
Anteil
Individual Investor
15.84%
Investment Advisor
11.61%
Corporation
5.58%
Investment Advisor/Hedge Fund
4.21%
Research Firm
0.60%
Hedge Fund
0.18%
Bank and Trust
0.07%
Venture Capital
0.05%
Pension Fund
0.03%
Other
61.83%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
123
14.61M
38.17%
+89.36K
2025Q1
124
14.64M
40.12%
+123.60K
2024Q4
115
14.16M
40.30%
-9.06K
2024Q3
108
15.43M
44.70%
+1.86M
2024Q2
83
13.39M
40.93%
+2.95M
2024Q1
29
10.41M
31.81%
+483.30K
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
O'Heeron (Peter)
5.91M
15.44%
--
--
Apr 21, 2025
Golden Knight Inc LP
2.13M
5.58%
+9.85K
+0.46%
Apr 21, 2025
BlackRock Institutional Trust Company, N.A.
1.63M
4.27%
-25.68K
-1.55%
Mar 31, 2025
The Vanguard Group, Inc.
1.42M
3.71%
+508.69K
+55.79%
Mar 31, 2025
Geode Capital Management, L.L.C.
614.64K
1.61%
+9.71K
+1.61%
Mar 31, 2025
State Street Global Advisors (US)
566.45K
1.48%
-8.07K
-1.40%
Mar 31, 2025
Cascade Financial Partners, LLC
260.08K
0.68%
-22.52K
-7.97%
Mar 31, 2025
Northern Trust Investments, Inc.
201.64K
0.53%
-13.77K
-6.39%
Mar 31, 2025
UBS Financial Services, Inc.
112.86K
0.29%
-15.33K
-11.96%
Mar 31, 2025
Optivise Advisory Services, LLC
110.10K
0.29%
--
--
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
iShares Russell 2000 Growth ETF
0%
ProShares Hedge Replication ETF
0%
Global X Russell 2000 ETF
0%
ProShares UltraPro Russell2000
0%
Proshares Ultra Russell 2000
0%
Texas Capital Texas Small Cap Equity Index ETF
0%
iShares Russell 2000 ETF
0%
iShares Micro-Cap ETF
0%
iShares Russell 2000 Growth ETF
Anteil0%
ProShares Hedge Replication ETF
Anteil0%
Global X Russell 2000 ETF
Anteil0%
ProShares UltraPro Russell2000
Anteil0%
Proshares Ultra Russell 2000
Anteil0%
Texas Capital Texas Small Cap Equity Index ETF
Anteil0%
iShares Russell 2000 ETF
Anteil0%
iShares Micro-Cap ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
